Peter Attia· MD
So this whole connection between everything that insulin does goes through PI3 kinase, and most oncogenes manage to activate PI3 kinase
Loading…
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
So this whole connection between everything that insulin does goes through PI3 kinase, and most oncogenes manage to activate PI3 kinase
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
And so, by 19... it was very clear in my mind that insulin was triggering cell growth in exactly the same way that oncogenes were. They were both activating PI3 kinase.
And as we began to explore what those mutations did, we realized they increased the ability of insulin to activate the enzyme.
Whole-body MRI screening in healthy adults produces more incidentaloma harm than cancer-mortality benefit.
Starting colonoscopy screening at 45 (vs 50) prevents enough early-onset cancers to justify the population cost.
Multi-cancer liquid-biopsy tests like Galleri detect early cancers at a stage that meaningfully improves survival.